StreetAlpha.app
Home › Stocks › RLAY

Relay Therapeutics, Inc. (RLAY)

Healthcare
$16.47
▼ −4.63%
LAST CLOSE · NOV 17

Relay Therapeutics develops small molecule drugs for patients with cancer and genetic disease. It last closed at $16.47 on Nov 17, down 4.63% on the day. The average 12-month price target from 2 analysts is $30.00 (+82.1% from the last close), with a high of $31.00 and a low of $29.00. Over the past 90 days StreetAlpha recorded 1 whale options trade in RLAY, 0% of them bullish and 100% bearish. In the past 30 days there were 6 dark pool prints totaling $9.7M, the largest $2.7M.

AI Auto Pilots
Is RLAY in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$10.3M
+23.9% vs a year ago
Net income
−$293.6M
−2837.0% margin
EPS (diluted)
−$1.50
Free cash flow
−$214.0M
−2067.8% margin
Valuation
Market cap
$3.6B
221.0M shares
P/E
–
No P/E while losing money
Price to sales
351.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$124.2M
At Sep 30
Shareholder equity
$819.0M
Shares outstanding
221.0M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $3.0M$3.0MFY2021FY2022: $1.4M$1.4MFY2022FY2023: $25.5M$25.5MFY2023FY2024: $10.0M$10.0MFY2024FY2025: $15.4M$15.4MFY2025

From RLAY's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated RLAY in the past 90 days, not enough for a consensus
Average 12-month target
$30.00
▲ 82.1% upside

Based on 2 analysts who set a price target on RLAY in the past 90 days. The average target is $30.00, with a high of $31.00 and a low of $29.00, compared with the last close of $16.47.

$12$19$26$32PAST 10 TRADING DAYS12-MONTH TARGETSHIGH $31AVG $30LOW $29Jun 2LAST CLOSE+12 MO$12$19$26$32PAST 10 DAYSTARGETSHIGH $31AVG $30LOW $29Jun 2LAST CLOSE+12 MO
Highest target$31.00
Average target$30.00
Lowest target$29.00
Latest rating changes
Jones TradingTarget raised
Nov 7Buy$18 → $31
HC Wainwright & Co.Target raised
Aug 20Buy$28 → $29
JP MorganTarget raised
Aug 14Buy$28 → $31
CitizensTarget raised
Aug 10Buy$21 → $26
BarclaysTarget raised
Aug 7Buy$27 → $30
DateFirmActionRatingPrice target
Nov 7Jones TradingTarget raisedBuy$18 → $31
Aug 20HC Wainwright & Co.Target raisedBuy$28 → $29
Aug 14JP MorganTarget raisedBuy$28 → $31
Aug 10CitizensTarget raisedBuy$21 → $26
Aug 7BarclaysTarget raisedBuy$27 → $30
Loading…

Technical Analysis

RLAY · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend

The stock is 12% below its 20 day and 11% below its 50 day average. It is 5% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 40). The nearest support is the swing low (Oct 16) at $16.13, and the nearest resistance the Pivot at $16.76.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityNormal, 6.9%/day
Key levels
$21.2752 week high+29.1%
$18.83100 day average+14.3%
$18.3820 day average+11.6%
$18.2850 day average+11.0%
$17.47Swing high (Jun 2)+6.1%
$17.13Pivot R1+4.0%
$16.76Pivot+1.8%
$16.47Last close
$16.13Swing low (Oct 16)−2.1%
$16.11Pivot S1−2.2%
$15.63200 day average−5.1%
$6.1752 week low−62.5%
Indicators
RSI (14)40.29Middle of its rangeNeutral
MACD-0.13Below its signal lineBearish
Stochastic17.9Near the bottom of its rangeOversold
ADX (14)15.4No clear trend
Williams %R-98.5Oversold below −80, overbought above −20Oversold
CCI (20)-146.7Oversold below −100, overbought above 100Oversold
Rate of change−5.6%Change over 10 sessionsBearish
ATR (14)$1.13Typical daily range, 6.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for RLAY

What happened before

See how RLAY did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow RLAY usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How RLAY has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
1
Bullish
0
0%
Bearish
1
100%
Date span
Oct 1 – Oct 1
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
6
Notional
$9.7M
Largest print
$2.7M
Loading…

RLAY Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●126 buying vs 114 selling
  • ▲Held by funds +2.8 pts
  • ●Funds holding +0
  • ▼Superinvestors: 1 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding2612610.0%
In funds' top 101211+9.1%
Held by funds114.5%111.7%+2.8 pts
New / increased33 / 9349 / 114−22.7%
Reduced / sold out83 / 3163 / 31+21.3%
Put/call ratio0.287.62−96.3%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RLAY institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RLAY is in one of them and how their past RLAY trades turned out.

RLAY in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RLAY in an article yet. Here's the latest on the wider market.

RLAY Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Aug 13
Who traded RLAY · since 2023
Latest 1 filing
$1K – $15KTraded Jul 12, 2023Filed Aug 13, 2023
PersonTypeAmountTradedFiledDelay
Dan GoldmanD · NYSell$1K – $15KJul 12, 2023Aug 13, 202332 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Relay Therapeutics

Relay Therapeutics is a biotechnology company based in Cambridge, Massachusetts, that develops small molecule drugs for patients with cancer and genetic disease. Its work centers on its Dynamo platform, which uses computational and experimental methods to study how proteins move and to design drugs for protein targets that conventional approaches have struggled to address. Its lead candidate, zovegalisib, is in clinical trials for breast cancer and for vascular anomalies. The company is still testing its therapies, so it does not yet sell medicines to patients.

Headquarters
Cambridge, MA
Founded
2016